Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

M. Podrazil, R. Horvath, E. Becht, D. Rozkova, P. Bilkova, K. Sochorova, H. Hromadkova, J. Kayserova, K. Vavrova, J. Lastovicka, P. Vrabcova, K. Kubackova, Z. Gasova, L. Jarolim, M. Babjuk, R. Spisek, J. Bartunkova, J. Fucikova,

. 2015 ; 6 (20) : 18192-205.

Language English Country United States

Document type Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020671

PURPOSE: We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with autologous mature dendritic cells (DCs) pulsed with killed LNCaP prostate cancer cells (DCVAC/PCa). The primary and secondary endpoints were safety and immune responses, respectively. Overall survival (OS), followed as a part of the safety evaluation, was compared to the predicted OS according to the Halabi and MSKCC nomograms. EXPERIMENTAL DESIGN: Twenty-five patients with progressive mCRPC were enrolled. Treatment comprised of initial 7 days administration of metronomic cyclophosphamide 50 mg p.o. DCVAC/PCa treatment consisted of a median twelve doses of 1 × 107 dendritic cells per dose injected s.c. (Aldara creme was applied at the site of injection) during a one-year period. The initial 2 doses of DCVAC/PCa were administered at a 2-week interval, followed by the administration of docetaxel (75 mg/m2) and prednisone (5 mg twice daily) given every 3 weeks until toxicity or intolerance was observed. The DCVAC/PCa was then injected every 6 weeks up to the maximum number of doses manufactured from one leukapheresis. RESULTS: No serious DCVAC/PCa-related adverse events have been reported. The median OS was 19 months, whereas the predicted median OS was 11.8 months with the Halabi nomogram and 13 months with the MSKCC nomogram. Kaplan-Meier analyses showed that patients had a lower risk of death compared with both MSKCC (Hazard Ratio 0.26, 95% CI: 0.13-0.51) and Halabi (Hazard Ratio 0.33, 95% CI: 0.17-0.63) predictions. We observed a significant decrease in Tregs in the peripheral blood. The long-term administration of DCVAC/PCa led to the induction and maintenance of PSA specific T cells. We did not identify any immunological parameter that significantly correlated with better OS. CONCLUSIONS: In patients with mCRPC, the combined chemoimmunotherapy with DCVAC/PCa and docetaxel was safe and resulted in longer than expected survival. Concomitant chemotherapy did not preclude the induction of specific anti-tumor cytotoxic T cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020671
003      
CZ-PrNML
005      
20160729104414.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.4145 $2 doi
035    __
$a (PubMed)26078335
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Podrazil, Michal $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
245    10
$a Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer / $c M. Podrazil, R. Horvath, E. Becht, D. Rozkova, P. Bilkova, K. Sochorova, H. Hromadkova, J. Kayserova, K. Vavrova, J. Lastovicka, P. Vrabcova, K. Kubackova, Z. Gasova, L. Jarolim, M. Babjuk, R. Spisek, J. Bartunkova, J. Fucikova,
520    9_
$a PURPOSE: We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with autologous mature dendritic cells (DCs) pulsed with killed LNCaP prostate cancer cells (DCVAC/PCa). The primary and secondary endpoints were safety and immune responses, respectively. Overall survival (OS), followed as a part of the safety evaluation, was compared to the predicted OS according to the Halabi and MSKCC nomograms. EXPERIMENTAL DESIGN: Twenty-five patients with progressive mCRPC were enrolled. Treatment comprised of initial 7 days administration of metronomic cyclophosphamide 50 mg p.o. DCVAC/PCa treatment consisted of a median twelve doses of 1 × 107 dendritic cells per dose injected s.c. (Aldara creme was applied at the site of injection) during a one-year period. The initial 2 doses of DCVAC/PCa were administered at a 2-week interval, followed by the administration of docetaxel (75 mg/m2) and prednisone (5 mg twice daily) given every 3 weeks until toxicity or intolerance was observed. The DCVAC/PCa was then injected every 6 weeks up to the maximum number of doses manufactured from one leukapheresis. RESULTS: No serious DCVAC/PCa-related adverse events have been reported. The median OS was 19 months, whereas the predicted median OS was 11.8 months with the Halabi nomogram and 13 months with the MSKCC nomogram. Kaplan-Meier analyses showed that patients had a lower risk of death compared with both MSKCC (Hazard Ratio 0.26, 95% CI: 0.13-0.51) and Halabi (Hazard Ratio 0.33, 95% CI: 0.17-0.63) predictions. We observed a significant decrease in Tregs in the peripheral blood. The long-term administration of DCVAC/PCa led to the induction and maintenance of PSA specific T cells. We did not identify any immunological parameter that significantly correlated with better OS. CONCLUSIONS: In patients with mCRPC, the combined chemoimmunotherapy with DCVAC/PCa and docetaxel was safe and resulted in longer than expected survival. Concomitant chemotherapy did not preclude the induction of specific anti-tumor cytotoxic T cells.
650    _2
$a adenokarcinom $x imunologie $x mortalita $x sekundární $x terapie $7 D000230
650    _2
$a metronomické podávání léků $7 D059250
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a alkylační protinádorové látky $x aplikace a dávkování $7 D018906
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a dendritické buňky $x imunologie $x transplantace $7 D003713
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x škodlivé účinky $x metody $x mortalita $7 D007167
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a tumor infiltrující lymfocyty $x imunologie $7 D016246
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nomogramy $7 D049451
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x imunologie $x mortalita $x patologie $7 D064129
650    _2
$a rizikové faktory $7 D012307
650    _2
$a T-lymfocyty - podskupiny $x imunologie $7 D016176
650    _2
$a taxoidy $x aplikace a dávkování $7 D043823
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horvath, Rudolf $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Becht, Etienne $u Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers, Paris, France. Université Pierre et Marie Curie-Paris, Paris, France. Université Paris Descartes, Paris, France.
700    1_
$a Rozkova, Daniela $u Sotio, Prague, Czech Republic.
700    1_
$a Bilkova, Pavla $u Sotio, Prague, Czech Republic.
700    1_
$a Sochorova, Klara $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Hromadkova, Hana $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Kayserova, Jana $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Vavrova, Katerina $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Lastovicka, Jan $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Vrabcova, Petra $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Kubackova, Katerina $u Department of Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Gasova, Zdenka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Jarolim, Ladislav $u Department of Urology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Babjuk, Marek $u Department of Urology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Spisek, Radek $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Bartunkova, Jirina $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Fucikova, Jitka $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 6, č. 20 (2015), s. 18192-205
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26078335 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160729104638 $b ABA008
999    __
$a ok $b bmc $g 1155341 $s 945199
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c 20 $d 18192-205 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options